The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-8068 injection in combination with anti-tumor therapies in subjects with colorectal cancer.
Subjects must voluntarily agree to participate in the trial and sign a written informed consent form.
Male or female ≥ 18 years old and ≤75 years old.
ECOG performance status of 0-1.
Part A with a life expectancy of ≥2 years. Part B with a life expectancy of ≥12 weeks.
Part B: Accompanied by untreated or active central nervous system (CNS) metastases. Subjects with a history or current history of meningeal metastasis.
Part B: Systemic antitumor therapy was received 4 weeks before the start of the study.
Part B: Palliative radiotherapy was completed within 14 days before the first dose.
Toxicity and/or complications from previous interventions did not return to NCI-CTCAE level ≤1 or exclusion criteria.